Highlights Teva Pharmaceutical Industries Limited London S.E.

Equities

0LER

US8816242098

Market Closed - London S.E. Other stock markets 09:00:00 31/05/2024 pm IST			5-day change	1st Jan Change
16.9 ^USD	+3.21%		+1.19%	+61.95%

30/05	Teva Pharmaceutical Gains FDA Approval for Daily Huntington's Disease Pill	MT
30/05	Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24?48 mg/day)	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24?48 mg/day)	30/05	CI
Teva Pharmaceutical Industries Limited and Alvotech Announce SIMLANDI® Injection Now Available in the U.S	21/05	CI
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	08/05	MT
Teva Pharmaceutical Shares Rise After Reporting Higher Q1 Earnings, Revenue; 2024 Guidance Reaffirmed	08/05	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	08/05	MT
Sector Update: Health Care	08/05	MT
Teva Pharmaceutical Industries Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed	08/05	MT
Earnings Flash (TEVA) TEVA PHARMACEUTICAL INDUSTRIES LIMITED Posts Q1 Revenue $3.82B	08/05	MT
Earnings Flash (TEVA) TEVA PHARMACEUTICAL INDUSTRIES LIMITED Posts Q1 EPS $0.48	08/05	MT
Teva Pharm Q1 profit falls short of estimates, revenue gains	08/05	RE
Teva Pharmaceutical Industries Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024	08/05	CI
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	01/05	MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	30/04	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04	MT
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	30/04	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04	MT
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	30/04	MT
Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	23/04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 03:11 pm IST

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 03, 2023 at 12:49 am IST